Eukaryotic Initiation Factor (eIF) Inhibitor

Eukaryotic Initiation Factor (eIF) Inhibitors (47):

Cat. No.	Product Name	Effect	Purity

HY-112654

GCN2iB	Inhibitor	99.90%
GCN2iB is an ATP-competitive inhibitor of a serine/threonine-protein kinase general control nonderepressible 2 (GCN2), with an IC₅₀ of 2.4 nM.

HY-112163

Zotatifin	Inhibitor	99.70%
Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC₅₀=2 nM) and interferes with the assembly of the eIF4F initiation complex. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC₉₀=37 nM). Zotatifin induces cell apoptosis.

HY-100877

GCN2-IN-1	Inhibitor	≥98.0%
GCN2-IN-1 (A-92) is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC₅₀ of <0.3 μM in the enzyme assay and an IC₅₀ of 0.3-3 μM in the cell assay.

HY-19356

Rocaglamide	Inhibitor	99.34%
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.

HY-168106

ZMF-24	Inhibitor
ZMF-24 is an anti-triple-negative breast cancer (TNBC) agent with IC₅₀ values of 0.22 μM and 0.44 μM against TNBC proliferation in BT-549 cells and MDA-MB-231 cells, respectively. ZMF-24 inhibits Eukaryotic translation initiation factor 3 subunit D (EIF3D) that disrupts the energy supply of TNBC by inhibiting glycolysis and further induces profound TNBC apoptosis by stimulating persistent ER stress.

HY-169123

DMDA-PatA	Inhibitor
DMDA-PatA is a small-molecule eIF4A inhibitor that represses translation in an mRNA-selective and ATP-independent manner by clamping eIF4A, a DEAD-box RNA binding protein, onto GNG motifs. DMDA-PatA is promising for research of cancers and viral infections.

HY-164524

SBI-0640726	Inhibitor
SBI-0640726 is an eIF4G1 inhibitor with antiproliferative activity in melanoma. SBI-0640726 disrupts the eIF4F translation initiation complex by inhibiting AKT and NF-kB signaling pathways. SBI-0640726 inhibits the growth of NRAS and BRAF mutant melanoma in vitro.

HY-19831

4EGI-1	Inhibitor	99.91%
4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a K_d of 25 μM against eIF4E binding.

HY-13251

Silvestrol	Inhibitor	99.96%
Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from Agave americana Linn.. Silvestrol induces autophagy and caspase-mediated apoptosis.

HY-14427

4E1RCat	Inhibitor	98.99%
4E1RCat is an inhibitor of cap-dependent translation, and inhibits eIF4E:eIF4GI interaction, with an IC₅₀ an of ∼4 μM.

HY-136453

CR-1-31-B	Inhibitor	98.36%
CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells.

HY-130240

GCN2-IN-6	Inhibitor	98.89%
GCN2-IN-6 (Compound 6d) is a potent, and orally available GCN2 inhibitor confirmed by in-house enzymatic (IC₅₀ of 1.8 nM) and cellular assays (IC₅₀ of 9.3 nM). GCN2-IN-6 is also a eIF2α kinase PERK inhibitor with an IC₅₀ of 0.26 nM (in enzymatic assay) and 230 nM (in cells). GCN2-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-101785

eIF4A3-IN-2	Inhibitor	99.70%
eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC₅₀ of 110 nM.

HY-101513

eIF4A3-IN-1	Inhibitor	99.96%
eIF4A3-IN-1 (compound 53a) is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor (IC₅₀=0.26 μM; K_d=0.043 μM), which binds to a non-ATP binding site of eIF4A3 and shows significant cellular nonsense-mediated RNA decay (NMD) inhibition at 10 and 3 μM and can be as a probe for further study of eIF4A3, the exon junction complex (EJC), and NMD.

HY-19560

SBI-0640756	Inhibitor	99.75%
SBI-0640756 (SBI-756) is an inhibitor of eIF4G1 and disrupts the eIF4F complex.

HY-100733

4E2RCat	Inhibitor	≥98.0%
4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC₅₀ of 13.5 μM.

HY-16366

Briciclib	Inhibitor	99.63%
Briciclib (ON 014185) is a derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.

HY-148422

Rohinitib	Inhibitor	99.40%
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML.

HY-19356A

Didesmethylrocaglamide	Inhibitor	98.49%
Didesmethylrocaglamide, a derivative of Rocaglamide, is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. Didesmethylrocaglamide has potent growth-inhibitory activity with an IC₅₀ of 5 nM. Didesmethylrocaglamide suppresses multiple growth-promoting signaling pathways and induces apoptosis in tumor cells. Antitumor activity.

HY-145262

eIF4E-IN-2	Inhibitor	98.76%
eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e). eIF4E-IN-2 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 1188). eIF4E-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Name
Email *

	Sorry, but the email address you supplied was invalid.